Mesoblast (MESO) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zenas BioPharma (ZBIO) has outperformed Mesoblast (MESO) over the past year, gaining 35.2% versus a loss of 22.9%. Mesoblast is the larger company by market cap ($1.79 billion vs $1.71 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MESO | ZBIO |
|---|---|---|
| Share price | $13.75 | $26.24 |
| Market cap | $1.79B | $1.71B |
| 1-day change | -1.36% | -6.88% |
| YTD return | -22.73% | -22.39% |
| 1-year return | -22.94% | +35.16% |
| 5-year return | +22.71% | — |
| Forward P/E | 30.22 | — |
| EPS (TTM) | $-0.44 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.50 | $44.60 |
| 52-week low | $13.05 | $13.50 |
| Distance from 52-week high | -36.05% | -41.17% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +169.09% | +82.47% |
| Average volume | 232.53K | 735.12K |
| Shares outstanding | 129.85M | 65.18M |
| Employees | 108 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBIO has outperformed MESO by 58.1 percentage points over the past year.
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
MESO vs ZBIO FAQ
Which is bigger, Mesoblast or Zenas BioPharma?
Mesoblast (MESO) is larger, with a market capitalization of $1.79B compared with $1.71B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, MESO or ZBIO?
ZBIO returned +35.16% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Mesoblast and Zenas BioPharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Mesoblast and Biotechnology: Pharmaceutical Preparations for Zenas BioPharma.